‘No evidence of disease activity’ - is it an appropriate surrogate in multiple sclerosis?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
‘No evidence of disease activity’ - is it an appropriate surrogate in multiple sclerosis?
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NEUROLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-04-24
DOI
10.1111/ene.13669
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients
- (2017) Jordi Río et al. Multiple Sclerosis Journal
- “No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis
- (2017) Gavin Giovannoni et al. Multiple Sclerosis Journal
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients
- (2017) Jordi Río et al. Multiple Sclerosis Journal
- “No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis
- (2017) Gavin Giovannoni et al. Multiple Sclerosis Journal
- Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis—The PaSiMS II study
- (2017) Gabriel Bsteh et al. PLoS One
- Long-term evolution of multiple sclerosis disability in the treatment era
- (2016) et al. ANNALS OF NEUROLOGY
- Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients
- (2016) Harald Hegen et al. DRUGS
- Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
- (2016) Tomas Uher et al. Multiple Sclerosis Journal
- The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis
- (2016) Diego Cadavid et al. Multiple Sclerosis Journal
- Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
- (2016) Ludwig Kappos et al. Multiple Sclerosis Journal
- Importance of early treatment initiation in the clinical course of multiple sclerosis
- (2016) Andrius Kavaliunas et al. Multiple Sclerosis Journal
- Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
- (2016) Tomas Uher et al. Multiple Sclerosis Journal
- The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis
- (2016) Diego Cadavid et al. Multiple Sclerosis Journal
- Importance of early treatment initiation in the clinical course of multiple sclerosis
- (2016) Andrius Kavaliunas et al. Multiple Sclerosis Journal
- Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
- (2016) Ludwig Kappos et al. Multiple Sclerosis Journal
- Defining high, medium and low impact prognostic factors for developing multiple sclerosis
- (2015) Mar Tintore et al. BRAIN
- Overview of the management of relapsing−remitting multiple sclerosis and practical recommendations
- (2015) P. Gallo et al. EUROPEAN JOURNAL OF NEUROLOGY
- Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
- (2015) J Kuhle et al. Multiple Sclerosis Journal
- No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy
- (2015) Alfredo Damasceno et al. Multiple Sclerosis Journal
- MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients
- (2015) Nature Reviews Neurology
- Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review
- (2015) Timothy Vollmer et al. NEUROLOGICAL SCIENCES
- Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis
- (2015) Martina Novotna et al. NEUROLOGY
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2015) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
- (2015) Dalia L. Rotstein et al. JAMA Neurology
- Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
- (2015) J Kuhle et al. Multiple Sclerosis Journal
- No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy
- (2015) Alfredo Damasceno et al. Multiple Sclerosis Journal
- Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
- (2015) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Freedom from disease activity in multiple sclerosis
- (2015) E. Havrdova et al. NEUROLOGY
- A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity
- (2015) Gro O. Nygaard et al. PLoS One
- Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis
- (2014) Sandra Meyer-Moock et al. BMC Neurology
- Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations
- (2014) Mark S. Freedman et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Established and novel disease-modifying treatments in multiple sclerosis
- (2014) A. H. Cross et al. JOURNAL OF INTERNAL MEDICINE
- Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study
- (2014) Cecilie Jacobsen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
- (2014) O. Tuohy et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Relapses and disability accumulation in progressive multiple sclerosis
- (2014) M. M. Paz Soldan et al. NEUROLOGY
- Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model
- (2014) Martin Stangel et al. Therapeutic Advances in Neurological Disorders
- Brain atrophy and lesion load predict long term disability in multiple sclerosis
- (2013) Veronica Popescu et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- Body fluid biomarkers in multiple sclerosis
- (2013) Manuel Comabella et al. LANCET NEUROLOGY
- Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study
- (2013) L Lavorgna et al. Multiple Sclerosis Journal
- Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis
- (2013) Luca Prosperini et al. Multiple Sclerosis Journal
- Defining and scoring response to IFN-β in multiple sclerosis
- (2013) Maria Pia Sormani et al. Nature Reviews Neurology
- Reliability of Longitudinal Brain Volume Loss Measurements between 2 Sites in Patients with Multiple Sclerosis: Comparison of 7 Quantification Techniques
- (2012) F. Durand-Dubief et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Scoring treatment response in patients with relapsing multiple sclerosis
- (2012) MP Sormani et al. Multiple Sclerosis Journal
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Early treatment in multiple sclerosis
- (2011) Irina Elovaara JOURNAL OF THE NEUROLOGICAL SCIENCES
- Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
- (2011) Per Soelberg Sorensen et al. LANCET NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability
- (2010) Antonio Scalfari et al. BRAIN
- Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis
- (2010) Chen S Tan et al. LANCET NEUROLOGY
- Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
- (2010) Raju Kapoor et al. LANCET NEUROLOGY
- Brainstem lesions in clinically isolated syndromes
- (2010) M. Tintore et al. NEUROLOGY
- Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
- (2010) N. De Stefano et al. NEUROLOGY
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
- (2009) Eva Havrdova et al. LANCET NEUROLOGY
- Measures in the first year of therapy predict the response to interferon β in MS
- (2009) J Río et al. Multiple Sclerosis Journal
- Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode
- (2009) DS Goodin et al. Multiple Sclerosis Journal
- Clinical prognostic factors in multiple sclerosis: a natural history review
- (2009) Alexandra Degenhardt et al. Nature Reviews Neurology
- Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures
- (2009) Hans-Jürgen Huppertz et al. NEUROIMAGE
- Impact of multiple sclerosis relapses on progression diminishes with time
- (2009) H. Tremlett et al. NEUROLOGY
- Gray matter atrophy in multiple sclerosis: A longitudinal study
- (2008) Elizabeth Fisher et al. ANNALS OF NEUROLOGY
- Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis
- (2008) L. K. Fisniku et al. BRAIN
- Natural history of multiple sclerosis in a population-based cohort
- (2008) M. Debouverie et al. EUROPEAN JOURNAL OF NEUROLOGY
- Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients
- (2008) J Río et al. Multiple Sclerosis Journal
- Early treatment of multiple sclerosis to prevent neurologic damage
- (2008) P. K. Coyle NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now